InnovoTEX Inc., a pre-clinical stage oncology therapeutics company, announced on Wednesday that it has named Tarak D Mody, PhD as its new director.

In the new role, Dr Mody is to use his extensive expertise in oncology business development, licensing and in forging strategic alliances with pharma and biotech organisations, to expedite development of the platform.

Dr Mody has served in the biopharmaceutical industry for several decades. Presently, he serves as chief business officer at the Parker Institute for Cancer Immunotherapy (PICI). He earlier worked as vice president of Business Development & Alliance Management at Five Prime Therapeutics. He has 20 years of experience at Pharmacyclics Inc. (now AbbVie, Inc.). He has served as a member of the original scientific team prior to transitioning into business development, where he was instrumental in the multi-asset acquisition from Celera Genomics, which included Bruton's tyrosine kinase (BTK) inhibitor discovery programs. He headed business development and intellectual property at Pharmacyclics.